Flagship Pioneering, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Flagship Pioneering, LLC reported 6 stock positions worth $843.4 million. Its top holding was Moderna (MRNA) at 65.2% of the portfolio, followed by Sana Biotechnology (SANA, 16.2%) and Foghorn Therapeutics (FHTX, 8.6%). Compared with Q1 2024, it sold out of 1 and reduced 1. The biggest sale was Moderna (MRNA, shares −52%).
- Most Recent 13F
- Q2 2026
- Location
- CAMBRIDGE, MA
- CIK
- 0001400240
- Portfolio Value
- $843.4M (Q2 2024)
- SEC Filing
- 0000950123-24-008727 ↗ filed Aug 14, 2024
Holdings Value
Holdings 6 stocks · $843.4M
| MRNA Moderna Inc. | 65.22% | 4,632,149 | $550.1M | Reduce -52.1% |
| SANA Sana Biotechnology Inc. | 16.19% | 25,001,856 | $136.5M | No change |
| FHTX Foghorn Therapeutics Inc. | 8.64% | 12,674,120 | $72.9M | No change |
| OMGAQ Omega Therapeutics Inc. | 7.17% | 29,225,579 | $60.5M | No change |
| MCRB Seres Therapeutics Inc. | 1.98% | 23,117,045 | $16.7M | No change |
| SYRS Syros Pharmaceuticals Inc. | 0.79% | 1,293,849 | $6.7M | No change |
Portfolio Sells Q1 2024 → Q2 2024
Portfolio Buys Q1 2024 → Q2 2024
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 5 | $1.5B | GENB, MRNA, SANA, FHTX, MCRB |
| Q1 2026 | 5 | $1.2B | GENB, MRNA, SANA, FHTX, MCRB |
| Q4 2025 | 4 | $324.0M | MRNA, SANA, FHTX, MCRB |
| Q3 2025 | 4 | $292.6M | MRNA, SANA, FHTX, MCRB |
| Q2 2025 | 4 | $268.5M | MRNA, SANA, FHTX, MCRB |
| Q1 2025 | 4 | $235.8M | MRNA, FHTX, SANA, MCRB |
| Q4 2024 | 5 | $334.2M | MRNA, FHTX, SANA, OMGAQ, MCRB |
| Q3 2024 | 6 | $591.9M | MRNA, FHTX, SANA, OMGAQ, MCRB |
| Q2 2024 | 6 | $843.4M | MRNA, SANA, FHTX, OMGAQ, MCRB |
| Q1 2024 | 7 | $1.5B | MRNA, SANA, OMGAQ, FHTX, DNLI |